People who receive AstraZeneca’s COVID-19 vaccine have a slightly increased risk of bleeding problems, according to a study published June 9 in Nature Medicine. Researchers observed adults in Scotland ...
The advisory panel wasn't convinced that a clinical trial proved that early switching to camizestrant improved long-term survival rates.
FDA advisory panel backs AstraZeneca’s Truqap as the first targeted therapy for PTEN deficient metastatic hormone sensitive ...
While AstraZeneca has discontinued work on four assets—including one in asthma and another in acromegaly—the pharma has also ...
The British pharmaceutical group said it would continue to work with U.S. regulators on a review of its breast-cancer ...
Pharmaceutical company AstraZeneca on Tuesday said it planned to increase its total revenue to $80 billion by 2030 — up 75% from $45.8 billion in 2023. AstraZeneca said it will focus on its oncology, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results